Israel - engelsk - Ministry of Health

pharma medis - sevoflurane - liquid - sevoflurane 100 %v/v - sevoflurane - sevoflurane - general inhalation anesthetic.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

colgate-palmolive (u.k.) ltd - sodium fluoride - toothpaste - 5000 ppm - caries prophylactic agents

Irland - engelsk - HPRA (Health Products Regulatory Authority)

colgate-palmolive a/s - sodium fluoride - toothpaste - 5000 ppm - caries prophylactic agents; sodium fluoride

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wsd agribusiness pty ltd - rotenone from derris; magnesium fluorosilicate; sulfur - topical solution/suspension - rotenone from derris extract-plant active 13.0 g/kg; magnesium fluorosilicate mineral-fluorine active 400.0 g/kg; sulfur mineral-sulfur active 250.0 g/kg - parasiticides - sheep - off shears | sheep short wool (shorn) | ovine | sheep - off shears | sheep - shorn - sheep body louse | sheep face louse | sheep foot louse | sheep itch mite | sheep ked | damalinia ovis (prev. genus) | lice - synthetic pyrethroid re | psorobia ovis | sheep body lice

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - idarubicin hydrochloride, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: glycerol; water for injections; sodium hydroxide; dilute hydrochloric acid - idarubicin ebewe is indicated for use in acute myelogenous leukaemia (aml) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients. idarubicin ebewe may be used in combination chemotherapy regimens involving other cytotoxic agents.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - idarubicin hydrochloride, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: glycerol; dilute hydrochloric acid; water for injections; sodium hydroxide - idarubicin ebewe is indicated for use in acute myelogenous leukaemia (aml) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients. idarubicin ebewe may be used in combination chemotherapy regimens involving other cytotoxic agents.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - idarubicin hydrochloride, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections; dilute hydrochloric acid; glycerol - idarubicin ebewe is indicated for use in acute myelogenous leukaemia (aml) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients. idarubicin ebewe may be used in combination chemotherapy regimens involving other cytotoxic agents.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: povidone; ascorbyl palmitate; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 13.5 mg - drug delivery system, transdermal - excipient ingredients: ascorbyl palmitate; povidone; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 9 mg - drug delivery system, transdermal - excipient ingredients: ascorbyl palmitate; povidone; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.